Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study

Ionis Pharmaceuticals plans a 2026 FDA submission for zilganersen as a treatment for Alexander disease, an ultra-rare inherited neurological disorder. The antisense oligonucleotide developer has been moving toward commercializing drugs on its own rather than seeking partners. The post Ionis Pharma’s Drug for Rare Disease With No Approved Therapies Meets Goals of Pivotal Study appeared…

Read More

Maybe AI Doesn’t Read Blueprints

By KIM BELLARD Gosh, who knew that Jan 13 would be an AI day, with at least three major announcements about “blueprints” for its development going forward? Of course, these days every day is an AI day; trying to take in all AI-related news can be overwhelming. But before some other AI news drowns them…

Read More

If You Could read My Mind – Wait, You Can?

By KIM BELLARD Over the years, one area of tech/health tech I have avoided writing about are brain-computer interfaces (B.C.I.). In part, it was because I thought they were kind of creepy, and, in larger part, because I was increasing finding Elon Musk, whose Neuralink is one of the leaders in the field, even more…

Read More

Evaluating the Complexities of the Digital Operating Room

As operating environments become more complex, every element and system must be reliable, safe, and compliant with the web of regulations. Testing is the antidote to address these issues, however, this presents a significant testing burden. Here are some key challenges. The post Evaluating the Complexities of the Digital Operating Room appeared first on MedCity News.

Read More